Loading
A phase 1 trial of Deutenzalutamide run by Hinova Pharmaceuticals Inc., completed.
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics is a phase 1 interventional study registered as NCT03776968 by Hinova Pharmaceuticals Inc., with 47 participants enrolled, started 2017-10-24. Conditions recorded: Metastatic Castration Resistant Prostate Cancer. Interventions recorded: HC1119.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/